Cowen and Company Reaffirms Buy Rating for Myovant Sciences Ltd (MYOV)

Myovant Sciences Ltd (NASDAQ:MYOV)‘s stock had its “buy” rating restated by equities research analysts at Cowen and Company in a report released on Tuesday.

The analysts wrote, “Myovant reported a FQ2:18 net loss of $29.9MM and a 9/30 cash balance of.””

A number of other analysts have also recently commented on MYOV. Robert W. Baird restated a “buy” rating and issued a $20.00 price objective on shares of Myovant Sciences in a research report on Friday. Zacks Investment Research upgraded Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. JMP Securities restated an “outperform” rating and issued a $25.00 price objective (up from $23.00) on shares of Myovant Sciences in a research report on Wednesday, October 4th. Finally, Evercore ISI initiated coverage on Myovant Sciences in a research report on Wednesday, August 16th. They issued an “outperform” rating for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.00.

Shares of Myovant Sciences (NASDAQ MYOV) traded down $0.69 during trading hours on Tuesday, reaching $13.43. The company’s stock had a trading volume of 80,410 shares, compared to its average volume of 35,778. Myovant Sciences has a one year low of $9.92 and a one year high of $18.85.

WARNING: This article was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://sportsperspectives.com/2017/11/14/cowen-and-company-reaffirms-buy-rating-for-myovant-sciences-ltd-myov.html.

Several institutional investors have recently bought and sold shares of the company. OxFORD Asset Management LLP increased its position in shares of Myovant Sciences by 15.4% in the second quarter. OxFORD Asset Management LLP now owns 29,745 shares of the company’s stock valued at $348,000 after buying an additional 3,971 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Myovant Sciences by 36.3% in the first quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock valued at $279,000 after buying an additional 6,330 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Myovant Sciences by 331.9% in the first quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock valued at $194,000 after buying an additional 12,700 shares in the last quarter. Quantitative Systematic Strategies LLC purchased a new stake in shares of Myovant Sciences in the second quarter valued at approximately $165,000. Finally, JPMorgan Chase & Co. increased its position in shares of Myovant Sciences by 18.4% during the third quarter. JPMorgan Chase & Co. now owns 91,213 shares of the company’s stock worth $1,382,000 after purchasing an additional 14,203 shares in the last quarter.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply